Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment

Sundlöv, A. LU orcid and Sjögreen-Gleisner, K. LU (2021) In Clinical Oncology 33(2). p.92-97
Abstract

Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (177Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we... (More)

Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (177Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.

(Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Lu-DOTATATE, individualised, neuroendocrine tumours, personalised, PRRT, radionuclide therapy
in
Clinical Oncology
volume
33
issue
2
pages
6 pages
publisher
Elsevier
external identifiers
  • pmid:33189510
  • scopus:85096191768
ISSN
0936-6555
DOI
10.1016/j.clon.2020.10.020
language
English
LU publication?
yes
id
6d7326ca-137f-4fad-847c-d270c18ef07d
date added to LUP
2020-11-25 09:22:50
date last changed
2024-04-17 19:35:05
@article{6d7326ca-137f-4fad-847c-d270c18ef07d,
  abstract     = {{<p>Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (<sup>177</sup>Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.</p>}},
  author       = {{Sundlöv, A. and Sjögreen-Gleisner, K.}},
  issn         = {{0936-6555}},
  keywords     = {{Lu-DOTATATE; individualised; neuroendocrine tumours; personalised; PRRT; radionuclide therapy}},
  language     = {{eng}},
  month        = {{02}},
  number       = {{2}},
  pages        = {{92--97}},
  publisher    = {{Elsevier}},
  series       = {{Clinical Oncology}},
  title        = {{Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment}},
  url          = {{http://dx.doi.org/10.1016/j.clon.2020.10.020}},
  doi          = {{10.1016/j.clon.2020.10.020}},
  volume       = {{33}},
  year         = {{2021}},
}